We are currently enrolling for paid clinical trials investigating ketamine and ketamine like compounds.
Esketamine is an investigational, fast acting anti-depressant that is used to treat major depressive disorder. It works through a different pathway than currently available antidepressant medications.
It is a glutamate receptor modulator, and is thought act by managing the function of the NMDA receptor in the brain. It is thought to help restore synaptic connections in the brain.
It has shown, so far, to be fast acting- decreasing depression and suicidality in just a few days. It is being studied as the first drug to treat suicidal thinking. It has few side effects. It is currently being studied on a wide scale for greater safety and efficacy. It may be available to the general public soon.
It has been shown to be helpful in treatment resistant depression.
If you’d like to learn more about our current esketamine/ketamine like trials, please complete the form below: